Clinical Report: Prednisolone Linked to Metabolic Benefits

Overview

A randomized crossover trial indicates that once-daily low-dose prednisolone may provide modest cardiometabolic benefits compared to thrice-daily hydrocortisone in patients with adrenal insufficiency. The study found slower bone turnover and improvements in body weight and glycated hemoglobin levels with prednisolone.

Background

Adrenal insufficiency requires effective glucocorticoid replacement therapy to prevent complications. Conventional hydrocortisone therapy often necessitates multiple daily doses, which can affect patient adherence and quality of life. Understanding alternative therapies like prednisolone is crucial for optimizing treatment outcomes and minimizing risks associated with long-term steroid use.

Data Highlights

Key Findings

• Once-daily low-dose prednisolone (2-5 mg) was compared to thrice-daily hydrocortisone in a crossover trial.
• Prednisolone treatment resulted in slower bone turnover compared to hydrocortisone.
• Patients on prednisolone experienced greater reductions in body weight, waist circumference, and glycated hemoglobin.
• No significant differences in subjective health outcomes or overall safety were observed between the two treatments.
• Long-term clinical significance of the findings remains uncertain, necessitating further studies.

Clinical Implications

Clinicians may consider low-dose prednisolone as an alternative to hydrocortisone for patients with adrenal insufficiency, especially in cases where adherence is a concern. However, careful monitoring of bone health and metabolic parameters is essential due to the potential for subtle changes that may not translate into significant clinical outcomes.

Conclusion

The findings suggest that low-dose prednisolone may offer certain metabolic advantages over hydrocortisone in adrenal insufficiency, but further research is needed to confirm the long-term implications of these results.

Related Resources & Content

1. JAMA Network Open, 2023 -- Prednisolone Linked to Metabolic Benefits
2. Ophthalmology Management, 2014 -- Know the systemic effects of ocular steroid therapy
3. The Journal of Clinical Endocrinology & Metabolism -- Evaluating the Clinical Advantages of Extended-Release Hydrocortisone Formulations
4. Adrenal Insufficiency - Endotext - NCBI Bookshelf
5. The Journal of Clinical Endocrinology & Metabolism — Assessing the Efficacy and Safety of Dexamethasone in Hospitalized COVID-19 Patients with Diabetes: A Retrospective Cohort Analysis
6. Clinical Rheumatology — Effects of Low-Dose IL-2 Treatment on Metabolism in Primary Sjögren’s Syndrome: Results from a Double-Blind, Randomized Clinical Trial
7. A randomised double-blind crossover study: once-daily low-dose prednisolone compared with thrice-daily hydrocortisone in adrenal insufficiency
8. SUN-425 Dual Release Hydrocortisone Versus Conventional Steroids in the Treatment of Adrenal Insufficiency: A Systematic Review and Meta Analysis
9. Adrenal Insufficiency - Endotext - NCBI Bookshelf